BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Harbour BioMed and Insilico Medicine Partner to Accelerate AI-Driven Antibody Discovery

Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on...

February 21, 2025 | News

Syensqo and Emulseo Partner to Advance Microfluidic Innovations in Healthcare

Syensqo, a leading specialty chemicals company, is pleased to announce a strategic partnership with Emulseo, a French company specialized in formulations f...

February 21, 2025 | News

South Korea’s Brexogen Out-Licenses BxC-I17e to BMI Korea in Landmark Exosome Therapeutics Deal

Out-licenses BxC-I17e, Exosome-Based Therapeutics for New IndicationsKRW 3 Billion Non-Refundable Upfront Payment + Milestone Payments + Double-Digit ...

February 20, 2025 | News

Bambusa Therapeutics Closes $90 Million Series A to Advance Bispecific Antibody Pipeline for Immunological and Inflammatory Disorders

Bambusa Therapeutics, Inc. (Bambusa), a biotechnology company developing bispecific antibodies for immunological and inflammatory (I&I) disorders, anno...

February 17, 2025 | News

Alphamab Oncology Doses First Patient in Phase III Study of Anti-HER2 ADC JSKN003 for Platinum-Resistant Ovarian Cancer

Alphamab Oncology announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparat...

February 14, 2025 | News

Lion TCR Secures FDA Clearance for Phase 2 Trial of Pioneering mRNA TCR-T Therapy for Liver Cancer

Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug A...

February 12, 2025 | News

Pfizer and Astellas Announce Sustained Survival Benefit in Advanced Urothelial Cancer with PADCEV® and KEYTRUDA® Combination

Enfortumab vedotin plus pembrolizumab continues to demonstrate superior efficacy versus chemotherapy in a broad population, reinforcing the combination a...

February 11, 2025 | News

Alphamab Oncology and CSPC Launch Phase III Trial for Anti-HER2 ADC JSKN003 in Advanced Breast Cancer

Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has rece...

February 07, 2025 | News

Lunit Partners with SITC to Launch AI-Powered Research Program for Cancer Immunotherapy

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, has entered into a partnership with the Society ...

February 04, 2025 | News

Kazia Therapeutics Launches Clinical Trial for Paxalisib-Immunotherapy Combination in Advanced Breast Cancer

Kazia Therapeutics Limited an oncology-focused drug development company, is pleased to announce the regulatory approval and launch of a clinical trial eval...

January 31, 2025 | News

Ryght AI and Cancer Research South Australia Partner to Accelerate Cancer Clinical Trials in Australia with AI

Ryght AI, a leading provider of real-time generative AI solutions for the clinical research industry, and Cancer Research South Australia (CRSA), a premier...

January 29, 2025 | News

Clarity Pharmaceuticals Secures Second FDA Fast Track Designation for 64Cu-SAR-bisPSMA in Prostate Cancer Imaging

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation product...

January 27, 2025 | News

GC Cell Hosts Landmark Symposium in Indonesia to Spotlight Immuncell-LC Cancer Immunotherapy

GC Cell, a leading cell and gene therapy company, announced the successful completion of its first thought leadership symposium in Jakarta, Indonesia....

January 24, 2025 | News

GI Innovation and LaNova Medicines Join Forces for Breakthrough Pancreatic Cancer Combination Therapy

GI Innovation (KQ:358570) announced that it signed a Memorandum of Understanding (MOU) with LaNova Medicines (LaNova) for the development o...

January 23, 2025 | News

Stay Connected